The Hunt for the Next 10 Bagger

[Newguy417]

MCVI .017 5 million float….9 million OS REINSTATEMENT (Merger?)
Active with SOS
http://da.sos.state.mn.us/minnesota/corp_inquiry-entity.asp?:nfiling_number=7J-436&entity_type_id=DC&:Nsession_id=&:Ndocument_number=0&filename=-513508744.txt&pgcurrent=6&:Norder_item_type_id=10&:Ssearch_Parm=medical+cv

These reinstatements are indicative of an impending merger.

Posted by: locksflooring ?Date: Tuesday, January 12, 2010 8:13:01 AM In reply to: None Post #? of 353

Heart health study in Great Lakes Bay Region includes stem cell therapy
By Jill Armentrout | The Saginaw News
January 11, 2010, 10:10AM
Michigan CardioVascular Institute and Covenant HealthCare of Saginaw are enrolling patients in a new stem cell therapy for heart attack patients.

The therapy, Prochymal, is a formulation of adult stem cells that may be able to prevent and treat heart damage after a severe heart attack. The trial will study the therapy’s ability to improve heart function, limit scar formation and preserve functional heart tissue after a patient’s first heart attack. Prochymal is an investigational therapy developed by Osiris Therapeutics Inc.

Dr. Safwan Kassas with MCVI infused the first trial patient with the therapy Dec. 21 at Covenant.

The Phase I trial involved 53 patients, who saw heart function improved and irregular heartbeats reduced after treatment, compared with a placebo group.

A heart attack occurs when blood flow is suddenly and completely blocked. More than half a million Americans will have their first heart attacks this year. American Heart Association data shows that within six years of a recognized heart attack, 18 percent of men and 35 percent of women have a repeat attack. A heart attack can significantly weaken heart muscle, which can lead to chronic heart failure.

This Phase 2 trial will include about 220 patients who come to the emergency room for treatment in the United States and Canada. Those eligible will have had their first heart attacks within the previous seven days. They will receive Prochymal or a placebo along with their present course of treatment.

Participation in the study includes a thorough health evaluation, study medications and laboratory testing. For information about the study and eligibility, call 583-6372.